1xbet 신청

Otsuka Pharmaceutical Co., Ltd. announces that it has received regulatory approval in Japan for t1xbet 신청 additional indication of suppression of recurrence and relapse of mood episodes in bipolar I disorder for ABILIFY MAINTENA (aripiprazole), a long-acting injectable suspension. T1xbet 신청 approved indication covers t1xbet 신청 300 mg and 400 mg vials (for injection) and t1xbet 신청 300 mg and 400 mg dual-chamber syringes.

ABILIFY MAINTENA is a depot preparation for intramuscular injection that administered monthly as a single injection.

Otsuka Pharmaceutical discovered ABILFY MAINTENA, an atypical antipsychotic, which first received regulatory approval in 2013 in t1xbet 신청 U.S. and E.U. for t1xbet 신청 treatment of adult schizophrenia. In 2015, it was approved in Japan for t1xbet 신청 same indication. In t1xbet 신청 U.S. and Canada, t1xbet 신청 indication as maintenance t1xbet 신청rapy for adult bipolar I maintenance t1xbet 신청rapy was added in 2017.